The Boston-based biopharmaceutical company claims Talabostat’s dual mechanism of action and positive results from the phase II study were the key components of the application for fast track
Evoltra has been granted orphan drug designation, providing marketing exclusivity for 10 years in Europe following this approval and can now be marketed throughout all 25 member states
Israel-based Teva claims the study observing patients with relapsing-remitting MS found that Copaxone lowered their annual relapse rate 57% more than Avonex, and that that neurologic disability, did
Preliminary analysis showed that MLN1202 was well tolerated and fully met its primary endpoint of a significant reduction in C-Reactive Protein (CRP) levels, an inflammatory biomarker associated with
The drug is deigned to improve chronic inflammation in patients with CIAS1-Associated Periodic Syndromes (CAPS), a spectrum of rare genetic disorders. Fast track designation are designed to aid
Picoplatin is a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. The drug is designed to overcome platinum resistance associated
The trial, performed in collaboration with a team based in Leicester, UK, will oversee the vaccination of 560 healthy adult individuals. Conventional vaccines against H5 and H9 avian
The company voluntarily suspended the trial on March 14th 2006 after three serious cases of pericardial effusion – a condition characterized by an accumulation of fluid around the
Humaneering is KaloBios’s proprietary method for converting non-human antibodies into engineered human antibodies for therapeutic drug applications. The system has the advantage of maintaining epitope specificity and increasing
The company announced its intentions regarding the development of the drug following the recent completion of a pre-IND meeting with the FDA. Inspire expects to submit the IND
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.